IP Verse

Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof

Patent No. EP3782612 (titled "Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof") was filed by Celgene on May 14, 2009. The application was issued on Nov 8, 2023.

Patent Summary

Oral formulations of 5-azacytidine that release the drug substantially in the stomach and achieve high peak plasma concentrations, enabling effective treatment of hematological malignancies. These formulations achieve peak concentrations of at least 100 ng/mL and maintain therapeutic efficacy over 90 minutes, with a maximum plasma concentration of at least 200 ng/mL. The formulations are designed to release the drug in the stomach environment, where 5-azacytidine is primarily metabolized, and achieve this therapeutic window without enteric coating.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKAug 8, 2024ELKINGTON AND FIFE
HOFFMANN EITLEAug 8, 2024-
STADA ARZNEIMITTELAug 8, 2024KERNEBECK
TEVA PHARMACEUTICALSAug 8, 2024D YOUNG
HAMM & WITTKOPPJul 30, 2024-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3782612

CELGENE
Application Number
EP20201143A
Filing Date
May 14, 2009
Status
Granted And Under Opposition
Oct 6, 2023
Publication Date
Nov 8, 2023
External Links
Slate, Register , Google Patents